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our genetic data suggests that ApoL1 is performing a critical role in the kidney that is impaired in the setting of the ApoL1 variants, although toxicity of the ApoL1 variants remains a possibility.
We have shown that both ApoL1 variants lyse a deadly subspecies of Trypanosoma that is normally completely resistant to ApoL1 lytic activity. The G2 mutation prevents the SRA virulence factor produced by T. b. rhodesiense from binding to and inactivating ApoL1. Even 10,000-fold dilutions of plasma containing these mutations (particularly G2) are active against the parasite. This raises the possibility that transfusion of small volumes of plasma, ApoL1-containing HDL particles, or recombinant protein might be effective treatment for trypanosomiasis caused by T. b. rhodesiense.
The kidney disease-associated variants are located on haplotypes that show statistical evidence of natural selection. The lytic activity of the variant proteins against Trypanosoma provides a plausible-albeit still speculativebiological explanation for natural selection. The results are consistent with a heterozygous advantage model because the protective effect against T. b. rhodesiense is dominant whereas the association with renal disease is recessive. Sickle cell disease is a well-established precedent for a model in which mutations conferring heterozygote advantage against a parasitic infection can confer a strong biological disadvantage for homozygotes (26) . When present in heterozygous form, certain hemoglobin mutations confer protection against malaria but when homozygous cause severe diseases of the red blood cell (for example, sickle cell disease and thalassemia).
It will be interesting to determine the distribution of these mutations throughout sub-Saharan Africa. In present-day Africa, T. b. rhodesiense is found in the eastern part of the continent, whereas we noted high frequency of the trypanolytic variants and the signal of positive selection in a West African population. Changes in trypanosome biology and distribution and/or human migration may explain this discrepancy, or resistance to T. b. rhodesiense could have favored the spreading of T. b. gambiense in West Africa. Alternatively, ApoL1 variants may provide immunity to a broader array of pathogens beyond just T. b. rhodesiense, as a recent report linking ApoL1 with anti-Leishmania activity may suggest (27) . Thus, resistance to T. b. rhodesiense may not be the only factor causing these variants to be selected.
The APOL1 risk alleles for renal disease occur in more than 30% of African-American chromosomes. Given their high frequency and their strong effect on disease risk, unraveling the molecular mechanisms by which they contribute to renal injury will be of great importance in understanding and potentially preventing renal disease in individuals of recent African ancestry.
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An 84-nucleotide c-di-GMP-II RNA from Clostridium difficile strain 630 (termed 84 Cd) ( Fig. 1B ) was 5′ 32 P-labeled and subjected to inline probing (10, 11) . The pattern of spontaneous RNA cleavage products generated without c-di-GMP (Fig. 1C) is consistent with our secondary structure model. Furthermore, 11 linkages exhibit reduced strand scission in 10 mM c-di-GMP, which indicates that these nucleotides are structurally stabilized on second messenger binding. Probing using a range of c-di-GMP concentrations reveals one-to-one binding with an apparent dissociation constant (K D ) of~200 pM ( Fig. 1D and  fig. S3 ). K D values for analogs are more than three orders of magnitude poorer ( Fig. 1E ), revealing molecular discrimination comparable to that exhibited by c-di-GMP-I riboswitches (7) .
Riboswitch function by other c-di-GMP-II RNAs was validated in vivo using riboswitch-reporter gene fusions (fig. S4, A and B) and in vitro using transcription termination assays (fig. S4, C and D). However, the 84 Cd aptamer lacks normal riboswitch control structures and is lo-cated~600 nucleotides upstream of the putative start codon for its associated open reading frame (ORF) ( Fig. 2A ). This unusually large gap has all the hallmarks of a group I self-splicing ribozyme (12, 13) ( fig. S5 ); therefore, we speculated that the RNAs may collaborate to function as an allosteric ribozyme wherein splicing is controlled by c-di-GMP.
Allosteric ribozyme function was assessed by using an 864-nucleotide internally 32 P-labeled RNA (864 Cd Tandem) carrying the aptamer and ribozyme domains and part of the C. difficile CD3246 ORF ( Fig. 2B and fig. S5 ). Incubation of wildtype RNA with guanosine 5´-triphosphate (GTP) yields characteristic group I ribozyme products ( Fig. 2C and fig. S6 ). However, the amount of 5′E-3′E spliced exons increases substantially when both GTP and c-di-GMP are present ( Fig. 3, A and B). The dose-response curve for c-di-GMP induction of splicing fits a one-to-one interaction with half-maximal 5′E-3′E production occurring with 30-nM second messenger ( fig. S7 ).
Analysis of in vitro splice products (figs. S8 and S9) reveals an atypical 5′ splice site (ss). Total RNA isolated from cultured C. difficile 630 cells produced a dominant reverse transcription polymerase chain reaction product (fig. S10) with a splice junction determined by sequencing that corresponded to that found in our in vitro assays. Furthermore, the extent of splicing increases with culture age. This latter finding is consistent with allosteric activation of splicing by c-di-GMP, whose concentrations should increase with increasing cell density.
Another RNA product (3′E*), determined to be a fragment of the 3′ exon caused by GTP attack far from the 5′ ss ( fig. S8 ), is reduced in the presence of c-di-GMP ( Figs. 2C and 3D ). Production of both 5′E-3′E and 3′E* RNAs were monitored in subsequent assays. Aptamer mutants M1 and M2 that disrupt c-di-GMP binding no longer respond to the second messenger in splicing reactions (Fig. 2C and fig. S11 ). In contrast, mutant M3 that carries nucleotide changes to M2 to restore aptamer P3 stem formation recovers c-di-GMP-mediated splicing control (Fig.  2C) . Thus, c-di-GMP binding to the aptamer triggers increased production of spliced exons.
We noticed two alternative base-pairing structures, the anti-5′ ss stem (Fig. 2B, blue shading) and the alternative ribozyme P1 stem (green shading), that may explain c-di-GMP splicing control. Anti-5′ ss stem formation disrupts two base pairs of the ribozyme P1 stem, which subsequently favors formation of the alternative ribozyme P1 stem. Because c-di-GMP binding stabilizes aptamer substructures (Fig. 1C) , low c-di-GMP concentrations should favor anti-5′ ss stem formation and prevent GTP attack at the 5′ ss. Indeed, a 132-nucleotide construct encompassing the aptamer through nucleotide 130 of the tandem RNA yields an in-line probing pattern consistent with anti-5′ ss stem formation in the absence of second messenger ( fig. S12A ). Additional mutants were used to validate this c-di-GMP-mediated structural rearrangement ( fig. S12 , B to D). S8 ). Alternative base-pair interactions guiding allosteric function are shaded blue and green. (C) PAGE separation of products generated by self-splicing assays. NR, no reaction; C-IVS and L-IVS, circular and linear intervening sequences, respectively; Pre, 864-nucleotide precursor RNA (fig. S5) ; 5′E-3′E, spliced exons; 3′E*, 3′ fragment generated by GTP attack at an alternative site; Fragments, additional RNA products presumably created by IVS circularization. Data for some mutants is presented elsewhere (fig. S11 ). The role of the anti-5′ ss stem was further evaluated by establishing the effects of mutants M4, M5, and M6. Consistent with our model, mutants M4 and M5 disrupt regulation ( Fig. 2C  and fig. S11 ), whereas M6 combines these disruptive mutations to yield a construct that restores c-di-GMP binding and regulation. Mutations M7 through M11 were created to assess the importance of the ribozyme P1 stem and the alternative ribozyme P1 stem for allosteric control. Mutations M7 through M10 disrupt specific structures and exhibit expected reductions in particular RNA products. Most notably, normal c-di-GMP regulation is observed for M11, which combines several disruptive mutations to form an RNA that restores alternative base-pairing potential. Finally, M12 lacks any splicing activity due to disruption of the ribozyme's GTP binding site. These findings are consistent with an allosteric ribozyme mechanism wherein c-di-GMP regulates alternative base pairing between distal regions of the precursor mRNA.
Reactions with unlabeled 864 Cd Tandem RNA and [a-32 P]GTP (Fig. 3A) were conducted to estimate the observed rate constant (k obs ) values for GTP attack (Fig. 3B) . A near 13-fold increase in initial rate constant (first 15 min) was observed for GTP attack at the 5′ ss when both GTP and c-di-GMP are present (2.3 × 10 −2 min −1 ). In contrast, there is only a modest reduction in the initial rate constant for GTP attack at the alternative GTP 2 site. This same pattern of ribozyme modulation is observed when internally labeled RNAs are used (Fig. 3C) , which results in a 12fold increase in the initial k obs for spliced product formation in the absence of c-di-GMP.
Similar results are obtained by evaluating the yields of spliced exon and alternative attack products after incubating for 120 min (Fig. 3 , C and E). Without c-di-GMP, the ribozyme produces greater than 20-fold more alternative attack product than spliced exons (Fig. 3E,  left) . Nearly equal amounts are produced when c-di-GMP is present. This change is largely due to an~8-fold increase in spliced exon production as the ratio of alternative attack product in the absence versus the presence of c-di-GMP drops only modestly (Fig. 3E, right) . Thus, c-di-GMP enhances the production of fully spliced exons largely by favoring formation of the ribozyme P1.
The sequences and structures of the precursor mRNA and processed RNAs suggest a mechanism for translation control of the CD3246 ORF ( Fig. 4) . Although the UUG start codon predicted in annotated C. difficile genomes is atypical, this translation start site and initial polypeptide sequence is consistent with similar genes in related organisms. In the precursor RNA, the start codon resides in the right shoulder of the P10 stem (Fig. 4A ). This arrangement should restrict ribosome access and preclude translation, which is a common mechanism for translation control by riboswitches (3) . With sufficient c-di-GMP and GTP, ribozyme action yields a processed mRNA wherein the spliced junction resides in a perfect ribosome binding site (AGGAGG) located an optimal distance upstream of the start codon (Fig.  4B ). Thus, allosteric activation of ribozyme selfsplicing by c-di-GMP should favor translation. In contrast, ribozyme action in the absence of c-di-GMP favors GTP attack only four nucleotides upstream of the start codon. This product is trimmed of nucleotides that otherwise could serve as a ribosome binding site (Fig. 4C) , which should disfavor translation.
Bacteria naturally exploit tandem riboswitch architectures to create more complex gene control elements (14) (15) (16) (17) . Our findings add to this complexity by demonstrating how two ligandresponsive RNAs, a self-splicing ribozyme and a riboswitch aptamer, collaborate to function as an allosteric RNA requiring two RNA compounds (GTP and c-di-GMP) to promote splicing. This conjoined riboswitch-ribozyme system validates a prediction made more than 20 years ago (18) that some group I ribozymes could be controlled by nucleotide-derived alarmones. Also, this RNA is a natural mimic of an engineered ribozyme that controls splicing and gene expression in response to theophylline binding (19) .
Some group I ribozymes may independently function as riboswitches that sense GTP because sufficient levels must be present for splicing to oc-cur. If true, then the tandem riboswitch-ribozyme examined in this study may constitute a two-input control system that reads GTP and c-di-GMP concentrations to trigger splicing accordingly. Notably, GTP is the immediate biosynthetic precursor of c-di-GMP, and overproduction of this second messenger causes substantial decreases in GTP concentrations in vivo (20) .
The harnessing of group I ribozymes by some organisms is suggested by the observation that bacteriophage ribozyme splicing is diminished in a bacterial host when ribosome function is inhibited (21) . Moreover, the gene associations of some examples are conserved in evolutionarily distant species (13) , implying useful rather than purely selfish functions. Of at least 10 group I ribozymes present in C. difficile 630, 9 are associated with a transposase gene ( fig. S12 ), which facilitates mobility of selfish genetic elements. Only the allosteric ribozyme described in this work lacks a transposase gene, which suggests that this representative is not a selfish RNA but has a location and a function that benefits the host.
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